3SBio Inc. has submitted its application for a Phase I trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA). NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent) with extended half-life and increased biologic activity. Preclinical results have showed a promising pharmacokinetic profile, which would allow a once weekly injection schedule. The drug will be studied as a potential treatment for anemia associated with both chronic kidney disease and cancer. &...